COVID Continues To Impact Outsourced Manufacturing And Supply Chain Security
By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports
Each of the past three years, Industry Standard Research has included questions in its annual CDMO benchmarking research to better understand whether the pandemic has affected drug innovators’ outsourced manufacturing for small molecule drug substance, small molecule drug product, biologic drug substance, or biologic drug product. Among those who have been affected, we asked how their organization will mitigate the impact in the coming months and years. The data show that roughly half of respondents (53%) to the 2023 surveys confirmed the effects of the pandemic are still shaping their relationships and influencing their work with CDMOs. That’s a 3% reduction from the survey responses in 2022. Download the article to learn more.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.